Previous 10 | Next 10 |
– Updated results from MEDALIST Phase 3 trial show 47.1% of patients with anemia associated with myelodysplastic syndromes treated with luspatercept achieved red blood cell transfusion independence for ≥ 8 weeks and median total duration of clinical benefit was 83.6 weeks fo...
Acceleron Pharma (NASDAQ: XLRN ): Q3 GAAP EPS of -$0.86 misses by $0.04 . Revenue of $4.21M (+29.1% Y/Y) misses by $0.23M . Press Release More news on: Acceleron Pharma Inc., Earnings news and commentary, Healthcare stocks news,
- FDA’s review of luspatercept BLA for the beta-thalassemia and lower-risk MDS indications remains ongoing - - Six clinical abstracts accepted for presentation at the 61 st American Society of Hematology (ASH) Annual Meeting - Acceleron Pharma Inc. (Nasdaq:XLRN), a leading...
AES , ALE , AMRX , ANIP , AYR , BCOR , BKI , BLMN , BR , CARS , CBRE , CNHI , CNR , COTY , CPRI , CRCM , CRL , CSTE , CVIA , CVS , CWEN , CYBR , DEA , DNOW , DOC , ELAN , ENBL , ESPR , FUN , GCP , GEL , GIB , GLOG , GOLD , HUM , HZNP , IMOS , IONS , JE...
Acceleron Pharma Inc. (Nasdaq:XLRN) today announced it will host a webcast and conference call on Wednesday, November 6, 2019 at 10:00 a.m. EST to discuss its third quarter 2019 operating and financial results. The webcast will be accessible under "Events & Presentations" in the Inves...
Shares of Acceleron Pharma (NASDAQ: XLRN) fell 12% in September, according to data provided by S&P Global Market Intelligence , after the biotech reported disappointing results for its drug candidate ACE-083 in patients who have facioscapulohumeral muscular dystrophy (FSHD). Interestin...
Getting new drugs to market can be a tough business. Acceleron Pharma (NASDAQ: XLRN) is learning this the hard way, scrapping plans to continue development for its experimental drug, ACE-083, in treating patients who have facioscapulohumeral muscular dystrophy (FSHD). The drug showed ...
Citing disappointing results from a Phase 2 study, Acceleron Pharma (NASDAQ: XLRN ) will terminate development of ACE-083 for facioscapulohumeral muscular dystrophy. More news on: Acceleron Pharma Inc., Healthcare stocks news, Stocks on the move, Read more ...
– ACE-083 did not achieve statistically significant improvements in functional endpoints relative to placebo – – Acceleron to discontinue development of ACE-083 in facioscapulohumeral muscular dystrophy – – Topline results from the Phase 2 trial...
Acceleron Pharma Inc. (NASDAQ:XLRN), a leading biopharmaceutical company in the discovery and development of TGF-beta superfamily therapeutics to treat serious and rare diseases, today announced that the United States Food and Drug Administration (FDA) has granted Orphan Drug designation to s...
News, Short Squeeze, Breakout and More Instantly...
Acceleron Pharma Inc. Company Name:
XLRN Stock Symbol:
NASDAQ Market:
Acceleron Pharma Inc. Website:
Believes Transaction Comes at the Wrong Time, With the Wrong Price, and Following the Wrong Process Remains Confident in Company’s Standalone Opportunities – Given Strong Momentum and Near-Term Inflection Point Coming from Phase 3 Data Stands Ready to Hel...
In September, Merck (NYSE: MRK) announced plans to acquire Acceleron Pharma (NASDAQ: XLRN) for $11.5 billion. However, the big drugmaker recently revealed that it withdrew a key regulatory filing document related to the transaction. In this Motley Fool Live video ...